Dental and Medical Problems

Dent. Med. Probl.
Index Copernicus (ICV 2018) – 113.05
MNiSW – 20
Average rejection rate – 71.8%
Average waiting time at editors (to acceptance) – 18.38 days
ISSN 1644-387X (print)
ISSN 2300-9020 (online)
Periodicity – quarterly

Download PDF

Dental and Medical Problems

2015, vol. 52, nr 1, January-March, p. 33–38

Publication type: original article

Language: English

Creative Commons BY-NC-ND 3.0 Open Access

Salivary Level of Epidermal Growth Factor in Recurrent Aphthous Stomatitis

Stężenie nabłonkowego czynnika wzrostu w ślinie w aftach przewlekle nawracających

Farnaz Ramezani1,A,B, Ziba Maleki2,A, Hamed Mortazavi2,E, Siamak Sabour3,C, Zahra Yadegari4,B, Maryam Baharvand2,D,F

1 Oral Medicine Specialist, Private Practice, Tehran, Iran

2 Department of Oral and Maxillofacial Medicine, Dental School, Shahid Beheshti University of Medical Sciences, Tehran, Iran

3 Department of Clinical Epidemiology, School of Public Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran

4 Department of Oral Biology, Dental School, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Abstract

Background. Recurrent aphthous stomatitis (RAS) represents a very common oral lesion, affecting 5–60% of the general population. Different mechanisms might be involved in the etiopathogenesis of RAS, but to date, no single definite cause has been confirmed.
Objectives. The aim of this study was to compare salivary epidermal growth factor (EGF) levels in two phases of RAS (ulcerative and remission phases) and in healthy controls.
Material and Methods. In this case-control study, the salivary epidermal growth factor concentration (pg/mL) was measured in 18 consecutive dental patients with RAS compared to 18 healthy controls. The two groups were matched in terms of age, sex, and salivary flow rate. Unstimulated whole saliva samples were collected in the first 3 days after mucosal ulceration and two weeks after resolution of RAS and from healthy controls. Salivary epidermal growth factor (SEGF) concentration was measured using the sandwich ELISA technique.
Results. Saliva samples were obtained from 36 people, comprised of 21 women and 15 men. The mean of the salivary epidermal growth factor level in the ulcerative stage of RAS patients (1772.05 ± 954.13 pg/mL) was lower than in the remission stage (2020.17 ± 996.94 pg/ml) and the control group (2357.10 ± 1365.96 pg/mL), but the differences were not significant.
Conclusion. Recurrent aphthous stomatitis has no effect on the salivary level of epidermal growth factor.

Key words

saliva, epidermal growth factor, recurrent aphthous stomatitis

Słowa kluczowe

ślina, nabłonkowy czynnik wzrostu, afty przewlekle nawrotowe

References (31)

  1. Jurge S., Kuffer R., Scully C., Porter S.R.: Mucosal disease series. Number VI. Recurrent aphthous stomatitis. Oral Dis. 2006, 12, 1–21.
  2. Natah S.S., Konttinen Y.T., Enattah N.S., Ashammakhi N., Sharkey K.A., Häyrinen-Immonen R.: Recurrent aphthous ulcers today: a review of the growing knowledge. Int. J. Oral Maxillofac. Surg. 2004, 33, 221–234.
  3. Lehner T.: Autoimmunity in oral diseases, with special reference to recurrent oral ulceration. Proc. R Soc. Med. 1968, 61, 515–524.
  4. Greenberg M., Glick M., Ship J.: Burket’s Oral Medicine. BC Decker, Ontario 2008, 11th ed., 57–60.
  5. Pekiner F.N., Aytugar E., Demirel G.Y., Borahan M.O.: Interleukin-2, interleukin-6 and T regulatory cells in peripheral blood of patients with Behçet’s disease and recurrent aphthous ulcerations. J. Oral Pathol. Med. 2012, 41, 73–79.
  6. Najafi S., Firooze Moqadam I., Mohammadzadeh M., Bidoki A.Z., Yousefi H., Farhadi E., Tonekaboni A., Meighani G., Amirzargar A.A., Rezaei N.: Interleukin-10 gene polymorphisms in recurrent aphthous stomatitis. Immunol. Invest. 2014, 43, 405–409.
  7. Buño I.J., Huff J.C., Weston W.L., Cook D.T., Brice S.L.: Elevated levels of interferon gamma, tumor necrosis factor alpha, interleukins 2, 4, and 5, but not interleukin 10, are present in recurrent aphthous stomatitis. Arch. Dermatol. 1998, 134, 827–831.
  8. Wu H.G., Song S.Y., Kim Y.S., Oh Y.T., Lee C.G., Keum K.C., Ahn Y.C., Lee S.W.: Therapeutic effect of recombinant human epidermal growth factor (RhEGF) on mucositis in patients undergoing radiotherapy, with or without chemotherapy, for head and neck cancer: a double-blind placebo-controlled prospective phase. Cancer 2009, 115, 3699–3708.
  9. Procaccino F., Reinshagen M., Hoffmann P., Zeeh J.M., Lakshmanan J., McRoberts J.A., Patel A., French S., Eysselein V.E.: Protective effect of epidermal growth factor in an experimental model of colitis in rats. Gastroenterol. 1994, 107, 12–17.
  10. Noguchi S., Ohba Y., Oka T.: Effect of salivary epidermal growth factor on wound healing of tongue in mice. Am. J. Physiol. 1991, 260, E620–625.
  11. Murdoch-Kinch C.A., Russo N., Griffith S., Braun T., Eisbruch A., D’Silva N.J.: Recovery of salivary epidermal growth factor in parotid saliva following parotid sparing radiation therapy: a proof-of-principle study. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2011, 111, 64–70.
  12. Wu-Wang C.Y., Patel M., Feng J., Milles M., Wang S.L.: Decreased levels of salivary prostaglandin E2 and epidermal growth factor in recurrent aphthous stomatitis. Arch. Oral Biol. 1995, 40,1093–1098.
  13. Adişen E., Aral A., Aybay C., Gürer M.A.: Salivary epidermal growth factor levels in Behçet’s disease and recurrent aphthous stomatitis. Dermatol. 2008, 217, 235–240.
  14. Guh J.Y., Chen H.C., Chuang L.Y., Yang C.Y., Tsai J.H., Lai Y.H.: Significance of salivary epidermal growth factor in peptic ulcer disease in hemodialysis patients. Nephron 2001, 87, 134–138.
  15. Dagogo-Jack S., Rodger R.S., Kendall-Taylor P.: Increased salivary concentration of human epidermal growth factor in patients undergoing CAPD. Perit. Dial. Int. 1991,11, 270–273.
  16. Balls G.V., Bridges Jr S.L.: Vasculitis. Oxford University Press, Oxford 2008, 2nd ed, 648.
  17. Dumbrigue H.B., Sandow P.L., Nguyen K.H., Humphreys-Beher M.G.: Salivary epidermal growth factor levels decrease in patients receiving radiation therapy to the head and neck. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2000, 89, 710–716.
  18. Epstein J.B., Emerton S., Guglietta A., Le N.: Assessment of epidermal growth factor in oral secretions of patients receiving radiation therapy for cancer. Oral Oncol. 1997, 33, 359–363.
  19. Nair R.R., Warner B.B., Warner B.W.: Role of epidermal growth factor and other growth factors in the prevention of necrotizing enterocolitis. Semin Perinatol. 2008, 32, 107–113.
  20. Balicki R., Grabowska S.Z., Citko A.: Salivary epidermal growth factor in oral cavity cancer. Oral Oncol. 2005, 41,48–55.
  21. Epstein J.B., Gorsky M., Guglietta A., Le N., Sonis S.T.: The correlation between epidermal growth factor levels in saliva and the severity of oral mucositis during oropharyngeal radiation therapy. Cancer 2000, 89, 2258–2265.
  22. Girdler N.M., McGurk M., Aqual S., Prince M.: The effect of epidermal growth factor mouthwash on cytotoxicinduced oral ulceration. A phase I clinical trial. Am. J. Clin. Oncol. 1995, 18, 403–406.
  23. Ohmura E., Emoto N., Tsushima T., Watanabe S., Takeuchi T., Kawamura M., Shigemoto M., Shizume K.: Salivary immunoreactive human epidermal growth factor (IR-hEGF) in patients with peptic ulcer disease. Hepatogastroenterol. 1987, 34, 160–163.
  24. Itoh M., Matsuo Y.: Gastric ulcer treatment with intravenous human epidermal growth factor: a double blind controlled clinical study. J. Gastroenterol. Hepatol. 1994, l9, S78–83.
  25. Haedo W., González T., Más J.A., Franco S., Gra B., Soto G., Alonso A., López-Saura P.: Oral human recombinant epidermal growth factor in the treatment of patients with duodenal ulcer. Rev. Esp. Enferm. Dig. 1996, 88, 409–418.
  26. Bakhtiari B., Bakkianian-Vaziri P., Hajolooi M., Mortazavi H.: Evaluation of serum levels of interleukin6 and interleukin-8 in patients with recurrent aphthous ulcerations. Health Med. 2010, 4, 522–525.
  27. Maleki Z., Sayyari A.A., Alavi K., Sayyari L., Baharvand M.: A study of the relationship between Helicobacter pylori and recurrent aphthous stomatitis using a urea breath test. J. Contemp. Dent. Pract. 2009, 10, 9–16.
  28. Mortazavi H., Namazi F., Badiei M.R., Bakhshi M.: Evaluation of therapeutic effects of Adcortyl and Myrtus communis (Myrtle) in patients with recurrent aphthous stomatitis: a clinical trial study. Health Med. 2012, 6, 1693–1698.
  29. Lin S.W., Tsai C.N., Lee Y.S., Chu S.F., Chen N.H.: Gene expression profiles in peripheral blood mononuclear cells of asian obstructive sleep apnea patients. Biomed. J. 2014, 37, 60–70.
  30. Huang T.L., Li C.F., Huang H.Y., Fang F.M.: Correlations between expression of epidermal growth factor receptor (EGFR), phosphorylated EGFR, cyclooxygenase-2 and clinicopathological variables and treatment outcomes in nasopharyngeal carcinomas. Chang Gung Med. J. 2010, 33, 619–627.
  31. Hung M.S., Lin C.K., Leu S.W., Wu M.Y., Tsai Y.H., Yang C.T.: Epidermal growth factor receptor mutations in cells from non-small cell lung cancer malignant pleural effusions. Chang Gung Med. J. 2006, 29, 373–379.